Ambagon Therapeutics
0 followers
‌
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.
Industries
Headquarters
Employees
Links
Org chart
Scott Clarke
CEO
Scott Clarke
Collapse
Christian Ottmann
Co-Founder & Chief Technology Officer
Nancy Pryer
Chief Scientific Officer
Maarten Altelaar
Executive Director
Neil Richardson
Contract Manager
Tanja Meyer
VP & Head, Corporate Strategy & Business Development
Thomas Marty
Vice President Finance
Zhen Zhang
Sr. Director
Peter Dudek
Board Director
